This report was first published by Endpoints News. To see the original version, click here
A biotech developing inhaled formulations of approved pulmonary fibrosis pills wants to tap the public markets to fund its late-stage work.
Avalyn Pharma submitted its pitch on Wednesday night for a Nasdaq listing under the ticker $AVLN. The Boston-based biotech didn’t say how much it seeks to raise, and companies typically lay out those goals after a period of marketing to investors to feel out demand.
您已阅读21%（495字），剩余79%（1908字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。